Senexin A, CAS 1366002-50-7

Product Description: Senexin A is an inhibitor of CDK8/19 (IC50: 280 nM, CDK8) and an inhibitor downstream of p21 transcription. It only inhibits p21-induced transcription but does not inhibit other biological effects of p21. Senexin A inhibits CMV-GFP induction as well as the p21 stimulatory activity of the consensus NF-κB-dependent promoters[1][2].

Applications: Cancer-Kinase/protease

Formula: C17H14N4

References: [1]Porter DC, et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13799-804./[2]Ho TY, et al. The study of a novel CDK8 inhibitor E966-0530-45418 that inhibits prostate cancer metastasis in vitro and in vivo. Biomed Pharmacother. 2023 Jun;162:114667.

CAS Number: 1366002-50-7

Molecular Weight: 274.32

Compound Purity: 99.79

Research Area: Cancer

Solubility: DMSO : ≥ 100 mg/mL

Target: CDK

• SKU: MEXHY-15681-10.1
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-15681-10.1
• Package Unit: 10 mM/1 ml
• Quantity Unit: STK